Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028

Published: Dec 2023 Pages: 163 SKU: IRTNTR73612

Phosphoinositide 3-Kinase (PI3K) Inhibitors Market 2024-2028

The Phosphoinositide 3-Kinase (PI3K) Inhibitors Market size is estimated to grow by USD 88.18 million at a CAGR of 5.54% between 2023 and 2028. 

There is an increase in the number of strategic alliances formed due to collaborations and license agreements are expected to help co-develop and commercialize PI3K inhibitors globally. In addition, co-development agreements enable the use of the technical expertise of both companies, which, in turn, would help them promote and support each other to develop and market novel drugs. Moreover, such agreements also ensure the in-flow of adequate funds for the companies involved and reduce liability costs incurred by individual companies in case of failures, thereby attracting more venture investments. Hence, such factors are positively impacting the market.

Technavio has segmented the market into  Application, Distribution Channel, and Geography

  • The application segment is classified into CLL, FL, and other indications.
  • The distribution channel  segment is classified into hospital pharmacies, retail pharmacies, and online pharmacies
  • The geography segment includes key regions such as North America, Europe, Asia, and the Rest of the World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018 - 2022, besides analyzing the current market scenario.

What will be the Size of the Phosphoinositide 3-Kinase (PI3K) Inhibitors Market During the Forecast Period?

To learn more about this report, Download Report Sample

Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Segmentation by Application, Distribution Channel, and Geography Analysis

Application Analysis

CLL

The CLL segment is estimated to witness significant growth during the forecast period. The chronic lymphocytic leukemia (CLL) segment of the global PI3K inhibitors market comprises SLL, as CLL and SLL come under the same category of lymphomas. In addition, in CLL, cancer cells are found mostly in the blood and bone marrow, whereas in SLL, cancer cells are found mostly in the lymph nodes. Even though only half of the PI3K inhibitors are approved for CLL, it was the major application in the global PI3K inhibitors market.

Get a glance at the market contribution of various segments Download PDF Sample

The CLL segment was the largest segment and was valued at USD 99.04 million in 2018. Moreover, the growth of this segment can be primarily attributed to the higher prevalence of CLL and SLL than FL globally. For example, according to the National Institutes of Health (NIH), the prevalence rate of CLL in 2022 was 25% to 30% of leukemias, and about 20,160 people had CLL in the US. In addition, the number of new cancer cases has increased significantly in recent years, owing to factors such as the increasing geriatric population and the increasing exposure to hazardous chemicals. Thus, several companies are conducting extensive research on developing novel therapeutics, such as PI3K inhibitors, to capture the huge unmet need. Hence, such factors are fuelling the growth of this segment which in turn drives the market growth during the forecast period.

Distribution Channel Analysis

Hospital pharmacies

The hospital pharmacies segment essentially serves as a liaison between pharmaceutical companies and healthcare providers, guaranteeing that PI3K inhibitors are available on hospital grounds. In addition, as PI3K inhibitors need close monitoring during treatment and their administration is complicated, this distribution model is especially pertinent to them. Moreover, hospitals are the major care settings for patients with cancer, and having these inhibitors on-site guarantees prompt access to necessary drugs. Furthermore, the specialized character of PI3K inhibitors and hospital chemists' experience managing complex medications complement each other, enhancing therapeutic efficacy and safety overall. Hence, such factors are fuelling the growth of this segment which in turn will drive the market growth during the forecast period.

Retail pharmacies

Retail pharmacies offer accessibility and convenience for patients looking for PI3K inhibitors, making them a vital distribution channel.  In addition, the understanding that many patients prefer getting their prescriptions filled at neighborhood pharmacies because of things like convenience, accessibility, and individualized care is the foundation for this channel segmentation. Moreover, pharmacists with training who work in retail pharmacies can provide helpful advice and information on how to use PI3K inhibitors correctly. Furthermore, the retail pharmacy market offers a venue for raising consumer awareness and education. Hence, such factors are fuelling the growth of this segment which in turn will drive the market growth during the forecast period

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 37% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The growth of the market in North America is fuelled by the sales of approved PI3K inhibitors and the increasing prevalence of several cancer indications, such as  CLL, FL, and breast cancer. As per BreastCancer.org, there were more than 3.5 million women in the US with a history of breast cancer in January 2020, and breast cancer death rates were greater than any other malignancy. Moreover, NSCLC and breast cancer are two of the most prevalent types of cancer in North America. Therefore, such a high prevalence of cancer demands advanced and specialized treatment options. Furthermore, targeted therapies such as PI3K inhibitors have the potential to meet this requirement. Therefore, the high prevalence of cancer indications is expected to drive the growth of the market in North America during the forecast period

Buy Full Report Now

Key Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 14 market companies, including:

Bayer AG: The company offers phosphoinositide 3 kinase inhibitor namely Copanlisib.

  • AbbVie Inc.
  • Celon Pharma SA
  • Curis Inc.
  • Eli Lilly and Co.
  • Exelixis Inc.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • Merck KGaA
  • Molecular Depot LLC
  • Novartis AG
  • TG Therapeutics Inc.
  • Verastem Inc.
  • Secura Bio Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Phosphoinositide 3-Kinase (PI3K) Inhibitors Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. 

Key Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Drivers

One of the key factors driving the phosphoinositide 3-kinase (PI3K) inhibitors market growth is the recent approvals of blood therapies. Even though several approved therapies are available for different types of blood cancer, the market experiences a huge unmet need for their treatment. In addition, many chemotherapy drugs are dominating the treatment landscape for several types of cancer, including lymphomas. However, chemotherapies have some limitations, which minimize patient adherence to the treatment.

Therefore, cancer treatment is experiencing a shift from traditional chemotherapy drugs to targeted therapies. In addition, the pharmacokinetics and pharmacodynamics of the treatment landscape for advanced or metastatic lymphomas, such as CLL, SLL, and FL, still have a scope for improvement. Hence such factors, through exhaustive research, targeted therapies such as PI3K inhibitors with proven efficacy in oncology applications are developed as suitable solutions for cancer treatment. Therefore, such factors are positively impacting the phosphoinositide 3-kinase inhibitor market. Hence, it is expected to drive the market growth during the forecast period.

Significant Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Trends

A key trend shaping the phosphoinositide 3-kinase (PI3K) inhibitors market growth is the rising adoption of reimbursement programs. In oncology treatment in the small molecules targeted therapy category, PI3K inhibitors are relatively new. In addition, the cost of these drugs is usually high, primarily due to the complex manufacturing process, which was a major challenge faced by the global PI3K inhibitors market for a long time.

Moreover, to overcome this challenge, various governments have come up with patient assistance programs to reduce the cost burden on patients and make them available at an affordable price. For example, Patient Protection and Affordable Care is an initiative taken by the US government that works to provide affordable health insurance. Therefore, such factors are positively impacting the Phosphoinositide 3-Kinase (PI3K) Inhibitors Market. Hence, it is expected to drive the market growth during the forecast period.

Major Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Challenges

Low adoption of therapeutic drugs is one of the key challenges hindering the phosphoinositide 3-kinase (PI3K) inhibitors market growth. PI3K inhibitor drugs exhibit strong adverse effects associated with the treatment of various indications. In addition, while PI3K inhibitors are often considered safe, the treatment using these drugs could cause severe adverse effects in some patients.

Moreover, a major share of the side effects in most of the patients are mild, such as swelling in the arms, hands, and legs; skin rashes; anemia; and infusion reactions. In addition in some cases, the side effects are very severe and could be life-threatening. Furthermore, these side effects also result in patients switching to alternative therapeutics for the treatment. Therefore, such factors are negatively impacting the phosphoinositide 3-kinase inhibitor market. Hence, it is expected to hinder the market growth during the forecast period.

Buy Now Full Report

Key Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Customer Landscape

Segment Overview

The phosphoinositide 3-kinase (PI3K) inhibitors market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

  •  Application Outlook
    • CLL
    • FL
    • Other indications
  • Distribution Channel Outlook
    • Hospital pharmacies
    • Retail pharmacies
    • Online pharmacies
  • Geography Outlook
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • Rest of the World (ROW)
      • Australia
      • Argentina
      • Brazil

Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Scope

Report Coverage

Details

Page number

163

Base year

2023

Historic period

2018-2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 5.54%

Market Growth 2024-2028

USD 88.18 million

Market structure

Concentrated

YoY growth 2023-2024(%)

4.48

Regional analysis

North America, Europe, Asia, and the Rest of the World (ROW)

Performing market contribution

North America at 37%

Key countries

US, Canada, Germany, UK, and China

Competitive landscape

 Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

AbbVie Inc., Bayer AG, Celon Pharma SA, Curis Inc., Eli Lilly and Co., Exelixis Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Merck KGaA, Molecular Depot LLC, Novartis AG, TG Therapeutics Inc., Verastem Inc., and Secura Bio Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the PI3K inhibitors market between 2024 and 2028
  • Precise estimation of the PI3K inhibitors market size and its contribution to the market in focus on the parent market
  • Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
  • Companies landscape comparing criticality of inputs and factors of differentiation
  • Exclusive Matrix on companies position and classification
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the market across North America, Europe, Asia, and the Rest of the World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive analysis of factors that will challenge the growth of phosphoinositide 3-kinase (PI3K) inhibitors market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2023
    • 3.4 Market outlook: Forecast for 2023-2028
      • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

    4 Historic Market Size

    • 4.1 Global phosphoinositide 3-kinase (PI3K) inhibitors market 2018 - 2022
      • Exhibit 18: Historic Market Size – Data Table on global phosphoinositide 3-kinase (pi3k) inhibitors market 2018 - 2022 ($ million)
    • 4.2 Application Segment Analysis 2018 - 2022
      • Exhibit 19: Historic Market Size – Application Segment 2018 - 2022 ($ million)
    • 4.3 Distribution Channel Segment Analysis 2018 - 2022
      • Exhibit 20: Historic Market Size – Distribution Channel Segment 2018 - 2022 ($ million)
    • 4.4 Geography Segment Analysis 2018 - 2022
      • Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ million)
    • 4.5 Country Segment Analysis 2018 - 2022
      • Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

    6 Market Segmentation by Application

    • 6.1 Market segments
      • Exhibit 30: Chart on Application - Market share 2023-2028 (%)
      • Exhibit 31: Data Table on Application - Market share 2023-2028 (%)
    • 6.2 Comparison by Application
      • Exhibit 32: Chart on Comparison by Application
      • Exhibit 33: Data Table on Comparison by Application
    • 6.3 CLL - Market size and forecast 2023-2028
      • Exhibit 34: Chart on CLL - Market size and forecast 2023-2028 ($ million)
      • Exhibit 35: Data Table on CLL - Market size and forecast 2023-2028 ($ million)
      • Exhibit 36: Chart on CLL - Year-over-year growth 2023-2028 (%)
      • Exhibit 37: Data Table on CLL - Year-over-year growth 2023-2028 (%)
    • 6.4 FL - Market size and forecast 2023-2028
      • Exhibit 38: Chart on FL - Market size and forecast 2023-2028 ($ million)
      • Exhibit 39: Data Table on FL - Market size and forecast 2023-2028 ($ million)
      • Exhibit 40: Chart on FL - Year-over-year growth 2023-2028 (%)
      • Exhibit 41: Data Table on FL - Year-over-year growth 2023-2028 (%)
    • 6.5 Other indications - Market size and forecast 2023-2028
      • Exhibit 42: Chart on Other indications - Market size and forecast 2023-2028 ($ million)
      • Exhibit 43: Data Table on Other indications - Market size and forecast 2023-2028 ($ million)
      • Exhibit 44: Chart on Other indications - Year-over-year growth 2023-2028 (%)
      • Exhibit 45: Data Table on Other indications - Year-over-year growth 2023-2028 (%)
    • 6.6 Market opportunity by Application
      • Exhibit 46: Market opportunity by Application ($ million)
      • Exhibit 47: Data Table on Market opportunity by Application ($ million)

    7 Market Segmentation by Distribution Channel

    • 7.1 Market segments
      • Exhibit 48: Chart on Distribution Channel - Market share 2023-2028 (%)
      • Exhibit 49: Data Table on Distribution Channel - Market share 2023-2028 (%)
    • 7.2 Comparison by Distribution Channel
      • Exhibit 50: Chart on Comparison by Distribution Channel
      • Exhibit 51: Data Table on Comparison by Distribution Channel
    • 7.3 Hospital pharmacies - Market size and forecast 2023-2028
      • Exhibit 52: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
      • Exhibit 53: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
      • Exhibit 54: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
      • Exhibit 55: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
    • 7.4 Retail pharmacies - Market size and forecast 2023-2028
      • Exhibit 56: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
      • Exhibit 57: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
      • Exhibit 58: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
      • Exhibit 59: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
    • 7.5 Online pharmacies - Market size and forecast 2023-2028
      • Exhibit 60: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
      • Exhibit 61: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
      • Exhibit 62: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
      • Exhibit 63: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
    • 7.6 Market opportunity by Distribution Channel
      • Exhibit 64: Market opportunity by Distribution Channel ($ million)
      • Exhibit 65: Data Table on Market opportunity by Distribution Channel ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 67: Chart on Market share by geography 2023-2028 (%)
      • Exhibit 68: Data Table on Market share by geography 2023-2028 (%)
    • 9.2 Geographic comparison
      • Exhibit 69: Chart on Geographic comparison
      • Exhibit 70: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2023-2028
      • Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ million)
      • Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ million)
      • Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
      • Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
    • 9.4 Europe - Market size and forecast 2023-2028
      • Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ million)
      • Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
      • Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
      • Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
    • 9.5 Asia - Market size and forecast 2023-2028
      • Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ million)
      • Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
      • Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
      • Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
      • Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
      • Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
      • Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
      • Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
    • 9.7 US - Market size and forecast 2023-2028
      • Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ million)
      • Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ million)
      • Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
      • Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
    • 9.8 Germany - Market size and forecast 2023-2028
      • Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ million)
      • Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
      • Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
      • Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
    • 9.9 China - Market size and forecast 2023-2028
      • Exhibit 95: Chart on China - Market size and forecast 2023-2028 ($ million)
      • Exhibit 96: Data Table on China - Market size and forecast 2023-2028 ($ million)
      • Exhibit 97: Chart on China - Year-over-year growth 2023-2028 (%)
      • Exhibit 98: Data Table on China - Year-over-year growth 2023-2028 (%)
    • 9.10 Canada - Market size and forecast 2023-2028
      • Exhibit 99: Chart on Canada - Market size and forecast 2023-2028 ($ million)
      • Exhibit 100: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
      • Exhibit 101: Chart on Canada - Year-over-year growth 2023-2028 (%)
      • Exhibit 102: Data Table on Canada - Year-over-year growth 2023-2028 (%)
    • 9.11 UK - Market size and forecast 2023-2028
      • Exhibit 103: Chart on UK - Market size and forecast 2023-2028 ($ million)
      • Exhibit 104: Data Table on UK - Market size and forecast 2023-2028 ($ million)
      • Exhibit 105: Chart on UK - Year-over-year growth 2023-2028 (%)
      • Exhibit 106: Data Table on UK - Year-over-year growth 2023-2028 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 107: Market opportunity by geography ($ million)
      • Exhibit 108: Data Tables on Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 109: Impact of drivers and challenges in 2023 and 2028
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 111: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 112: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 113: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 114: Matrix on vendor position and classification
            • 12.3 AbbVie Inc.
              • Exhibit 115: AbbVie Inc. - Overview
              • Exhibit 116: AbbVie Inc. - Product / Service
              • Exhibit 117: AbbVie Inc. - Key news
              • Exhibit 118: AbbVie Inc. - Key offerings
            • 12.4 Bayer AG
              • Exhibit 119: Bayer AG - Overview
              • Exhibit 120: Bayer AG - Business segments
              • Exhibit 121: Bayer AG - Key news
              • Exhibit 122: Bayer AG - Key offerings
              • Exhibit 123: Bayer AG - Segment focus
            • 12.5 Celon Pharma SA
              • Exhibit 124: Celon Pharma SA - Overview
              • Exhibit 125: Celon Pharma SA - Business segments
              • Exhibit 126: Celon Pharma SA - Key offerings
              • Exhibit 127: Celon Pharma SA - Segment focus
            • 12.6 Curis Inc.
              • Exhibit 128: Curis Inc. - Overview
              • Exhibit 129: Curis Inc. - Product / Service
              • Exhibit 130: Curis Inc. - Key offerings
            • 12.7 Eli Lilly and Co.
              • Exhibit 131: Eli Lilly and Co. - Overview
              • Exhibit 132: Eli Lilly and Co. - Product / Service
              • Exhibit 133: Eli Lilly and Co. - Key news
              • Exhibit 134: Eli Lilly and Co. - Key offerings
            • 12.8 Exelixis Inc.
              • Exhibit 135: Exelixis Inc. - Overview
              • Exhibit 136: Exelixis Inc. - Product / Service
              • Exhibit 137: Exelixis Inc. - Key offerings
            • 12.9 F. Hoffmann La Roche Ltd.
              • Exhibit 138: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 139: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 140: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 141: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 142: F. Hoffmann La Roche Ltd. - Segment focus
            • 12.10 Gilead Sciences Inc.
              • Exhibit 143: Gilead Sciences Inc. - Overview
              • Exhibit 144: Gilead Sciences Inc. - Product / Service
              • Exhibit 145: Gilead Sciences Inc. - Key news
              • Exhibit 146: Gilead Sciences Inc. - Key offerings
            • 12.11 Merck KGaA
              • Exhibit 147: Merck KGaA - Overview
              • Exhibit 148: Merck KGaA - Business segments
              • Exhibit 149: Merck KGaA - Key news
              • Exhibit 150: Merck KGaA - Key offerings
              • Exhibit 151: Merck KGaA - Segment focus
            • 12.12 Molecular Depot LLC
              • Exhibit 152: Molecular Depot LLC - Overview
              • Exhibit 153: Molecular Depot LLC - Product / Service
              • Exhibit 154: Molecular Depot LLC - Key offerings
            • 12.13 Novartis AG
              • Exhibit 155: Novartis AG - Overview
              • Exhibit 156: Novartis AG - Business segments
              • Exhibit 157: Novartis AG - Key offerings
              • Exhibit 158: Novartis AG - Segment focus
            • 12.14 Secura Bio Inc.
              • Exhibit 159: Secura Bio Inc. - Overview
              • Exhibit 160: Secura Bio Inc. - Product / Service
              • Exhibit 161: Secura Bio Inc. - Key offerings
            • 12.15 TG Therapeutics Inc.
              • Exhibit 162: TG Therapeutics Inc. - Overview
              • Exhibit 163: TG Therapeutics Inc. - Product / Service
              • Exhibit 164: TG Therapeutics Inc. - Key offerings
            • 12.16 Verastem Inc.
              • Exhibit 165: Verastem Inc. - Overview
              • Exhibit 166: Verastem Inc. - Product / Service
              • Exhibit 167: Verastem Inc. - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 168: Inclusions checklist
                • Exhibit 169: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 170: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 171: Research methodology
                • Exhibit 172: Validation techniques employed for market sizing
                • Exhibit 173: Information sources
              • 13.5 List of abbreviations
                • Exhibit 174: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              phosphoinositide 3-kinase (pi3k) inhibitors market market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis